BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7624919)

  • 1. Bayesian forecasting of serum vancomycin concentrations in neonates and infants.
    Rodvold KA; Gentry CA; Plank GS; Kraus DM; Nickel E; Gross JR
    Ther Drug Monit; 1995 Jun; 17(3):239-46. PubMed ID: 7624919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of gentamicin concentrations in neonates and infants using a Bayesian pharmacokinetic model.
    Rodvold KA; Gentry CA; Plank GS; Kraus DM; Nickel E; Gross JR
    Dev Pharmacol Ther; 1993; 20(3-4):211-9. PubMed ID: 7828456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic parameters of vancomycin in critically ill patients.
    Llopis-Salvia P; Jiménez-Torres NV
    J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations.
    Rodvold KA; Pryka RD; Garrison M; Rotschafer JC
    Ther Drug Monit; 1989; 11(3):269-75. PubMed ID: 2728085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients.
    Polard E; Le Bouquin V; Le Corre P; Kérebel C; Trout H; Feuillu A; Le Verge R; Mallédant Y
    Ther Drug Monit; 1999 Aug; 21(4):395-403. PubMed ID: 10442692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation.
    Asbury WH; Darsey EH; Rose WB; Murphy JE; Buffington DE; Capers CC
    Ann Pharmacother; 1993 Apr; 27(4):490-6. PubMed ID: 8477127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer dosing program for the initiation of vancomycin therapy.
    Ito MK; Duren LL; Simonian JS; Dreyfus-Vigil SD; Cookson TL
    Clin Pharm; 1993 Feb; 12(2):126-30. PubMed ID: 8453861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive performance of a vancomycin-aminoglycoside population model.
    Beringer PM; Wong-Beringer A; Rho JP
    Ann Pharmacother; 1998 Feb; 32(2):176-81. PubMed ID: 9496400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin.
    Garrelts JC; Godley PJ; Horton MW; Karboski JA
    Clin Pharm; 1987 Oct; 6(10):795-9. PubMed ID: 3505841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian forecasting of gentamicin pharmacokinetics in pediatric intensive care unit patients.
    Kraus DM; Dusik CM; Rodvold KA; Campbell MM; Kecskes SA
    Pediatr Infect Dis J; 1993 Sep; 12(9):713-8. PubMed ID: 8414796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.
    Marqués-Miñana MR; Saadeddin A; Peris JE
    Br J Clin Pharmacol; 2010 Nov; 70(5):713-20. PubMed ID: 21039765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin monitoring: one or two serum levels?
    Andrés I; López R; Pou L; Piñol F; Pascual C
    Ther Drug Monit; 1997 Dec; 19(6):614-9. PubMed ID: 9421100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Bayesian method for predicting vancomycin dosing.
    Burton ME; Gentle DL; Vasko MR
    DICP; 1989 Apr; 23(4):294-300. PubMed ID: 2728513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian forecasting of serum vancomycin concentrations with non-steady-state sampling strategies.
    Rodvold KA; Rotschafer JC; Gilliland SS; Guay DR; Vance-Bryan K
    Ther Drug Monit; 1994 Feb; 16(1):37-41. PubMed ID: 8160252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
    Kimura T; Sunakawa K; Matsuura N; Kubo H; Shimada S; Yago K
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1159-67. PubMed ID: 15047516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia.
    Zhang X; Wang D
    J Infect Chemother; 2020 May; 26(5):492-497. PubMed ID: 31983615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models.
    Pryka RD; Rodvold KA; Garrison M; Rotschafer JC
    Ther Drug Monit; 1989; 11(4):450-4. PubMed ID: 2741194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous rifampicin (rifampin) in neonates.
    Pullen J; Stolk LM; Degraeuwe PL; van Tiel FH; Neef C; Zimmermann LJ
    Ther Drug Monit; 2006 Oct; 28(5):654-61. PubMed ID: 17038881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters.
    Teramachi H; Hatakeyama H; Matsushita R; Imai Y; Miyamoto K; Tsuji A
    Biol Pharm Bull; 2002 Oct; 25(10):1333-8. PubMed ID: 12392090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.